Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHF5259 (glycopyrronium bromide)
- Development stage
- Phase 4
- Lead developer
- Chiesi
- Modality
- Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Inhalation
01
Overview
Glycopyrronium bromide (CHF5259) is an investigational extra-fine inhaled formulation of glycopyrrolate developed as a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD) and asthma. It acts by selectively antagonizing the muscarinic M3 receptor on bronchial smooth muscle cells, leading to bronchodilation and reduced mucus secretion. The drug is delivered via a pressurized metered dose inhaler (pMDI), allowing direct administration to the lungs. Clinical trials have shown that CHF5259 improves lung function in patients with moderate to severe COPD and has demonstrated a favorable safety profile[1][3][4].
- Other names
- extrafine glycopyrronium bromide pMDIglycopyrrolate
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)
Beyond the preview
Go deeper on CHF5259 (glycopyrronium bromide).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHF5259 (glycopyrronium bromide).